abstract |
The present invention relates to a secretagogue compound derived from oxalate degrading bacteria for use in the treatment of oxalate-related diseases and/or oxalate-related imbalances in a subject, wherein said secretagogue is administered Secretin results in a decrease in urinary oxalate and/or plasma oxalate in the subject. The present invention also relates to a pharmaceutical composition comprising such a secretagogue compound, a method of treating a subject suffering from an oxalate-related disease, and a method for preparing a secretagogue. |